Corinne Jenkins
Stock Analyst at Goldman Sachs
(1.25)
# 1808
Out of 5,218 analysts
75
Total ratings
43.75%
Success rate
10.48%
Average return
Main Sectors:
Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
Rhythm Pharmaceutica... | Maintains: Strong Buy | 59 66 | 55.28 | 19.39% | 8 | Dec 5, 2024 | |
TG Therapeutics | Maintains: Neutral | 20 22 | 32.03 | -31.31% | 8 | Nov 5, 2024 | |
Intra-Cellular Thera... | Maintains: Neutral | 77 74 | 83.02 | -10.86% | 5 | Aug 8, 2024 | |
Fulcrum Therapeutics | Upgrades: Buy | 6 15 | 3.97 | 277.83% | 2 | May 14, 2024 | |
IDEAYA Biosciences | Maintains: Buy | 53 46 | 25.19 | 82.61% | 5 | May 13, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 16 18 | 11.83 | 52.16% | 5 | Apr 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 4 5 | 3.86 | 29.53% | 3 | Mar 15, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Neutral | 13 | 8.98 | 44.77% | 3 | Jan 24, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Sell | 25 28 | 32.38 | -13.53% | 7 | Jan 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 47 52 | 38.38 | 35.49% | 5 | Nov 29, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 10 9 | n/a | n/a | 5 | Nov 15, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 332 296 | n/a | n/a | 2 | Nov 3, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 12 4 | 0.41 | 875.61% | 6 | Aug 15, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 27 23 | 0.91 | 2427.47% | 2 | Mar 15, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 25 21 | 3.23 | 550.15% | 2 | Mar 7, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 9 14 | 6.71 | 108.64% | 2 | Dec 20, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Sell | 2 | n/a | n/a | 1 | Aug 22, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 9 8 | 17.49 | -54.26% | 2 | May 24, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 16 | 0.58 | 2658.62% | 2 | Dec 15, 2021 |